Proteomics refers to the study of proteome to identify types of proteins, protein-protein & protein-nucleic acid interactions along with the post-translational modifications. It helps researchers to screen large number of proteins with clinically distinct properties to discover biomarkers, validate drug targets, design effective drugs, and assess drug efficacy & patient response. On the other hand, genomics is used to understand the structure and function of genomes in particular, genes. It measures entire DNA sequence of organisms, fine-scale genetic mapping, intra-genomic phenomenon, and other interactions within the genome. Both proteomics and genomics-based researches are used to study the molecular and genetic basis of diseases for the development of new drug molecules.

With traditional methods, studies related to proteomics and genomics have drawbacks, such as less accuracy and specificity, more time consuming, and low throughput. Due to this, the researchers were in search of molecular units that could effectively detect the potential candidates quantitatively, which gave rise to use of antibodies as specific reporter molecule to spot unique targets. Since then, antibody-based research for the species-specific diseasediagnosis and drug development came to existence as an inseparable part of the genomics and proteomics research.

Further, due to its inherent benefits, the development of antibody-based drugs and associated research activities skyrocketed globally, which led to a gradual increase in commercialization of antibody products. For instance, according to MedCrave online Journal (MOJ) of immunology, in 2017, FDA approved 10 monoclonal antibodies as compared to 3 in 2011. At the same time certain regulatory changes have also been made to fast track designation to antibodies and accelerated their approval. Due to this increase in antibody approvals, the government investments to facilitate antibody research projects has increased considerably, imparting high growth to the demand of research antibodies and reagents. Some of the major investments include:

  • In March 2018, the U.K. government announced investment of $279.9 million for development of precision medicines to identify individuals with rare diseases and aging population, which is expected to boost research activities for development of antibodies.
  • According to European Union (EU), the European government launched program Horizon 2020 in 2016, with an investment of $88.5 billion (€80 billion), of which around 10% (~$9 billion) was utilized for healthcare sector. The initiative was aimed to develop and support personalized medicine (including antibody development) projects. Also,during the period of 2014-2016, the European Commission invested more than $2.7 billion (€2.4 billion) in projects that supported innovation in personalized medicine.
  • In 2016, China announced precision medicine as part of its five-year plan, with an investment of $9 billion (60 billion yuan) for research.

In addition, due to increasing investments, many of the pharmaceutical companies globally joined hands with research institutes to improve their product offerings, ultimately booming the antibody-based research. For instance:

  • In June 2019, Amgen Inc. (U.S.) and University of Washington’s Institute for Protein Design (U.S.) announced collaboration for the development new technologies, which would optimize the Amgen’s repertoire of bispecific antibodies.
  • In February 2017, – Invenra, Inc. (U.S.) collaborated with QIMR Berghofer Medical Research Institute (Australia) for identification and characterization of monoclonal antibodies against novel targets to develop cancer therapies.
  • In April 2015, Innate Pharma S.A. (France) entered into a collaboration agreement with Sanofi S.A. (France) to utilize Innate Pharma’s site-specific conjugation technology for the development of new bispecific antibody formats with improved therapeutic index.

Hence, a growing focus on proteomic and genomics research studies and increasing investments in precision medicine research is steadily propelling the research antibodies and reagents market growth with a CAGR of 6% from 2019 to reach $14.56 billion by 2025, according to the Meticulous Research®.

The full report on the global Research Antibodies and Reagents Market , published by Meticulous Research®, can be accessed at:

Tags: Healthcare


Related Reports